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Although postoperative adjuvant chemotherapy (PAC) with uracil–tegafur significantly improves the prognosis of patients with stage
I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy.
Therefore, it is extremely important to identify patients for whom adjuvant chemotherapy will be beneficial. We performed
comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem
mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules. Furthermore, we carried out
immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS. We detected two kinds of
protein molecules (myosin IIA and vimentin) by LC-MS/MS. We confirmed their immunohistochemical expression and distribution,
and evaluated the relationship between the expression of these proteins and prognosis after adjuvant chemotherapy. Patients with
no expression of either myosin IIA or vimentin showed a significantly better outcome regardless of PAC using uracil–tegafur.
However, we were unable to select responders to uracil–tegafur using these proteins. Cases of adenocarcinoma lacking expression
of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment.
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Death due to lung cancer is still increasing in most industrialised
countries, including Japan, despite improvement of various
diagnostic and therapeutic modalities. Even though the opportu-
nities to detect lung cancer at an early stage are increasing,
approximately 60000 patients with lung cancer die every year in
Japan, usually due to distant metastasis. Distant metastasis,
including intrapulmonary metastasis, frequently occurs in patients
with advanced-stage non-small cell lung cancer (NSCLC) who
undergo only surgical resection, because in such cases micro-
metastases probably exist at the time of surgery. The concept of
postoperative adjuvant chemotherapy (PAC) for control of
micrometastasis does not conflict with the improved prognosis
of NSCLC patients. However, the efficacy of PAC in patients after
complete resection of NSCLC was a matter of controversy in the
1990s. Even as recently as 2003, the efficacy of PAC could not be
demonstrated (Scagliotti et al, 2003). In 2004, however, some
studies demonstrate a beneficial effect of PAC (Arriagada et al,
2004; Strauss et al, 2004; Winton et al, 2005). We have also
reported that PAC with oral uracil–tegafur (DPD Inhibitory
Fluoropyrimidine, Taiho Pharmaceutical Co. Ltd, Tokyo, Japan)
provided better survival than surgical treatment alone in patients
with stage I adenocarcinoma of the lung (Kato et al, 2004). The
combination of uracil and tegafur (also referred to as UFT) at a
molar ratio of 4:1 is an oral anticancer agent with good absorption
in the small intestine (Fujii et al, 1979). Tegafur is a prodrug that is
gradually converted into fluorouracil in the liver by the
cytochrome P-450 enzyme system. Uracil enhances the serum
concentration of fluorouracil by competitive inhibition of dihydro-
pyrimidine dehydrogenase, the enzyme responsible for fluoro-
uracil catabolism (Ikenaka et al, 1979). Oral uracil–tegafur
generates a higher maximal plasma level of fluorouracil than
protracted intravenous infusion of fluorouracil at a dose that is
equimolar to the amount of tegafur in uracil–tegafur (Ho et al,
1998).
Even though PAC with uracil–tegafur has significantly
improved the prognosis of patients with stage I primary lung
adenocarcinoma, even subset analysis of stage IB has revealed that
11.5% of patients actually derive some benefit from the treatment
(Kato et al, 2004). Nonresponders to uracil–tegafur, including
relapse-free patients without any adjuvant therapy, gain no benefit
from PAC. In this context, it is important to establish biomarkers
for prediction of responders to uracil–tegafur, and/or for
favourable prognosis without the use of PAC.
Clarification of the entire human genome is one of the most
significant events in the history of bioscience, and has accelerated
the comprehensive analysis of human genes and their protein
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sproducts. Many biologists recognise the importance of protein
analysis, because proteins play central role various cellular
functions. However, in cancer research, there has been a tendency
for most researchers to avoid investigation of cancer-related
proteins, because their structures are more complicated than those
of the genes. Nevertheless, techniques for the comprehensive
analysis of proteins have improved greatly in recent years. The
concept of comprehensive protein analysis has been established,
and the new research field of proteomics has been developed. One
of the main purposes of clinical proteomics in the field of oncology
is the development of new therapeutic strategies for cancer,
centred on individualised therapy. In this study, we attempted to
identify biomarkers for the selection of responders to uracil–
tegafur and nonresponders, including relapse-free patients without
any requirement for PAC, using clinical proteomics methodology.
MATERIALS AND METHODS
Institutional review board approval for this investigation
The institutional review board approved the use of proteomics
analysis to explore biomarkers for selection of responders to oral
uracil–tegafur (294/323/480/702).
Surgical samples of stage I lung adenocarcinoma for mass
spectrometry
After obtaining written informed consent, lung cancer tissues were
obtained from patients with pathologically confirmed stage I
adenocarcinoma resected at Tokyo Medical University Hospital
between 1995 and 2001. Tissues were kept frozen at  801C until
use. We collected 11 lung adenocarcinoma specimens from 11
patients who subsequently underwent PAC using uracil–tegafur
for more than 2 years. In 5 of these 11 patients, recurrent lesions
were detected within 2 years after surgery (U1R1), and the
remaining 6 were confirmed to be disease-free for 5 years after
surgery (U1R0). Furthermore, 13 specimens of lung cancer were
collected from patients receiving no adjuvant therapy after
surgery. In 6 of these 13 patients, recurrence was recognised
within 2 years after surgery (U0R1), but no recurrent lesions were
detected during 5 years after surgery in the other 7 (U0R0).
Protein extraction
The surgically resected materials were suspended and homoge-
nised in PBS supplemented with a protease inhibitor cocktail
(Roche Diagnostics Inc., Basel, Switzerland) at 41C. The cell lysate
was then fractionated by ultracentrifugation (52000g,4 1C,
20min). The resulting pellet containing plasma membranes from
the cells, was solubilised in PBS containing 5% SDS with
continuous ultrasonication. The resulting solution was taken as
the insoluble fraction, whereas the supernatant from the ultra-
centrifugation, containing mainly cytosolic proteins, was taken as
the soluble fraction. The total protein concentrations of both
fractions were measured (Lowry et al, 1951) using bovine serum
albumin as a standard.
Protein condensation with SDS-PAGE
We added 150pmol egg white lysozyme (Sigma-Aldrich Inc.,
St Louis, MO, USA) to an aliquot containing 75mg protein from
each fraction, then dried it under vacuum. The mixture was then
solubilised in sample buffer (Laemmli, 1970) with gentle stirring at
371C for 1h. A two-third volume of the solution containing 50mg
sample protein and 100pmol lysozyme was subjected to SDS-
PAGE on 12.5% polyacrylamide gel 1-mm-thick. SDS-PAGE was
carried out at a constant current of 20A until the bromophenol
blue marker passed the boundary between the stacking and
separation gels. In this ‘halfway’ running, most proteins remained
stacked in a small area of approximately 2mm in height between
the gel boundary and the blue marker. After electrophoresis, this
small gel area was excised from the gel slab, and the proteins were
fixed in the gel slice with an excess volume of aqueous solution
containing 40% methanol and 10% acetic acid.
In-gel tryptic digestion of protein
The gel slice was subjected to an in-gel tryptic digestion process
(Shevchenko et al, 1996), with minor modifications. Briefly, after
S-carboxyamidomethylation of Cys residues with iodoacetamide,
the gel slice was incubated in a small volume of 50mM ammonium
bicarbonate buffer solution containing 1mg of trypsin (Promega
Co., Madison, WI, USA). The resulting peptides were extracted
from the gel matrix, and dried under vacuum.
Liquid chromatography-tandem mass spectrometry
The peptide mixture (1mg) was analysed using a liquid chromato-
graphy-tandem mass spectrometry (LC-MS/MS) system in a fully
automated manner (Kawakami et al, 2005). Briefly, reversed-phase
peptide separation was performed on a C18 capillary LC column
(Michrom BioResources Inc., Auburn, CA, USA) at a flow rate of
1ml/min. For gasification of the protonated peptides, the LC
effluent was directly interfaced with an electrospray ionisation
(ESI) source in a positive ion mode modified on a Finnigan LTQ
linear ion trap mass spectrometer (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) (Schwartz et al, 2002). The ESI used a Teflon-
coated spray needle (20mm id, AMR Inc., Tokyo, Japan). The ESI-
MS/MS operation and continuous data acquisition of full MS scan
and subsequent three MS/MS scans were carried out on an
Xcalibur system controller (Thermo Fisher Scientific).
Semiquantitative analysis
All full MS data were investigated using an i-OPAL semiquanti-
tative LC-MS data analysis system (i-OPAL algorithm: Patent no.
WO 2004/090526 AI). First, the signal intensity of the full MS scan
was normalised so that the total signal intensity of each sample
became the same value. Several standard signals derived either
from the injected egg white lysozyme or from sample intrinsic
common proteins were selected as i-OPAL alignment markers. The
i-OPAL alignment programme was used to align the nonlinearly
fluctuating LC retention time axis of all LC-MS data to finally
generate a single combined LC-MS data set for the soluble and the
insoluble fractions, respectively. Analysis of variance (ANOVA)
was applied for each peak signal in the final combined LC-MS data
set to select candidate marker signals whose intensity differed
significantly in a particular patient group. ANOVA was carried out
using a Spotfire DecisionSite package.
Database searches
All MS/MS data were investigated using the Mascot search engine
(Matrix Science Ltd., London, UK, http://www. matrixscience.com)
against the Homo sapiens (human) subset of the Swiss-Prot and the
RefSeq protein sequence databases. The database searches were
performed allowing for fixed modification of cysteine residues
(S-carbamidomethylation, þ57.0Da) and variable modification
of methionine residues (oxidation, þ16.0Da), peptide mass
tolerance ±2.0Da and fragment m/z tolerance ±0.8.
Surgical specimens of stage I lung adenocarcinoma for
immunohistochemical staining
Sample set A for confirmation of LC-MS semiquantitative
results To confirm the semiquantitative results of LC-MS, 23
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same cases as those used for LC-MS analysis were collected for
immunohistochemical investigation. As one formalin-fixed speci-
men had already been exhausted for the previous investigations,
the remaining 23 specimens were investigated.
Sample set B for validation To validate the expression of the
protein molecules on lung adenocarcinoma cells, 90 formalin-
fixed, paraffin-embedded specimens from patients with lung
adenocarcinoma, resected at Tokyo Medical University Hospital
between 1995 and 2001, were used. All the patients had undergone
curative resection of lung cancer, and after surgery, a pathologi-
cally definitive diagnosis of stage I adenocarcinoma had been
obtained. We evaluated recurrence after surgery using chest
roentgenography and serum tumour markers (CEA, CA19-9 and
SLX) every 3 months and computed tomography of the head and
body, and bone scintigraphy, every 6 months. When it was difficult
to evaluate roentgenographically whether the lesion was recurrent
or not, either cytological or pathological examinations were
performed to obtain a definitive diagnosis (Table 1).
Of the 90 patients, 51 underwent PAC using uracil–tegafur.
These 51 cases included 24 recurrences (U1R1) within 5 years and
27 cases without recurrence (U1R0) within 5 years after surgical
treatment. The remaining 39 patients did not receive any adjuvant
chemotherapy. These 39 patients included 17 with recurrence
(U0R1) and 22 without recurrence (U0R0). The clinicopathological
backgrounds of the 90 patients with lung adenocarcinoma are
summarised in Table 2.
Immunohistochemical staining of surgically resected
specimens of stage I lung adenocarcinoma
Four-micrometer-thick tissue sections were prepared from for-
malin-fixed, paraffin-embedded surgical specimens and collected
on glass slides. The sections were stained immunohistochemically
by the ABC method using either anti-myosin IIA mouse
monoclonal antibody (clone ab24762, abcam, Cambridge, CB4
0FW, UK) (diluted 1:500) or anti-vimentin antibody (Dako
Cytomation, Denmark A/S) (diluted 1:100) as the first antibody.
After deparaffinisation, specimens were treated with 0.01% trypsin
and an autoclave antigen retrieval system (Barbareschi et al, 1994).
Sequentially, after inhibition of endogenous peroxidase activity
with 0.5% hydrogen peroxide and incubation with 2% normal
swine serum, the first antibody was applied. Biotinylated anti-
mouse immunoglobulin (Vector Laboratories Inc., Burlingam, CA,
USA) was applied as the second antibody (diluted 1:200), followed
by application with avidin–biotin peroxidase complex (Vector
Laboratories Inc.) (diluted 1:100). The specimens were reacted
with 0.06% 3,3’-diaminobenzidine tetrahydrochloride and 0.03%
hydrogen peroxide in Tris-buffered saline to visualise the positive
areas. Meyer’s haematoxylin was used for counterstaining.
Evaluation of immunohistochemically stained
preparations
Cells showing cytoplasmic staining were evaluated as positive. For
myosin IIA immunohistochemical staining, we evaluated a case as
positive when more than 50% of the cells were stained. Also, for
vimentin immunostaining, cases in which more than 25% of the
cells were stained were evaluated as positive. For both kinds of
staining, normal alveolar epithelium served as an internal negative
control.
Statistical analysis
Statistical analysis was carried out using the SPSS program.
Statistical significance of the relationship between recurrence
and immunohistochemical reactivity was evaluated using w
2 test.
Disease-free survival curves were calculated from the day of
surgery using the Kaplan–Meier method, and the significance of
differences in survival rates between the patient groups was
calculated by the log-rank test. In all statistical analyses, a P-value
of o0.05 was taken to indicate a statistically significant difference.
RESULTS
LC-MS data analysis
After i-OPAL alignment and peak detection, we obtained 13136
signal peaks from the soluble fraction and 14984 peaks from
the insoluble fraction. Using Spotfire, we restricted the candidate
signal peaks on the basis of the following conditions:
(1) A Mascot search result with a score equal to or more than 50.
(2) An ANOVA P-value equal to or less than 1 10
 5 (for the
soluble fraction) or 1 10
 6 (for the insoluble fraction).
Table 1 Clinical features of lung adenocarcinoma cases subjected to
LC-MS/MS
Characteristic (%)
Age (year)
Median 65.0
Range 32–78
Gender
Male 19 cases (79.2%)
Female 5 cases (20.8%)
Pathological stage
IA 10 cases (41.7%)
IB 14 cases (58.3%)
Presence of recurrence
(+) 11 cases (45.8%)
( ) 13 cases (54.2%)
PAC
(+) 11 cases (45.8%)
( ) 13 cases (54.2%)
PAC¼postoperative adjuvant chemotherapy with oral uracil–tegafur.
Table 2 Clinical features of lung adenocarcinoma cases as revealed by
immunohistochemical staining
Characteristic (%)
Age (year)
Median 64.8
Range 45–82
Gender
Male 54 cases (60.0%)
Female 36 cases (40.0%)
Pathological stage
IA 33 cases (36.7%)
IB 57 cases (63.3%)
Existence of recurrence
(+) 41 cases (45.6%)
( ) 49 cases (54.4%)
PAC with urasil-tegafur
(+) 51 cases (56.7%)
( ) 39 cases (43.3%)
PAC¼postoperative adjuvant chemotherapy.
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sAs the peptide compositions of the soluble and the insoluble
fractions differed, we applied different criteria to obtain approxi-
mately the same number of candidate signals. As a result, we were
able to restrict the number of candidate signals to 23 and 28 for the
soluble and insoluble fractions, respectively. From the restricted
candidate signals, we selected several myosin IIA and vimentin
signals as final candidate biomarker signals, because these two
candidate biomarkers were identified by more than one distinct
peptide sequence, and almost all of these signals had similar
patterns of intensity (Figure 1A and B; Table 3).
Table 3 lists the amino-acid sequences from the selected
candidate biomarker signals described above. These sequences
were identified from MS/MS data using Mascot software.
Figure 1A shows the distribution of the signal intensity of
several peptide ions derived from myosin IIA, and Figure 1B shows
the signal intensity distribution of vimentin-derived peptide ions.
For most signals, the intensity for group U1R1 patients showed
patterns that differed significantly (i.e., were markedly higher)
from those of the other patient groups.
Immunohistochemical staining of myosin IIA and
vimentin
Representative staining of myosin IIA and vimentin is shown in
Figure 2, and a summary of the immunohistochemical data is
presented in Table 4. Cytoplasmic staining was observed in cases
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Figure 1 Comparison of the intensity of peptide signals originating from the same protein molecule in each group detected by LC-MS. The vertical axis
indicates normalised signal intensity measured by LC-MS. In each box plot, the upper and lower sides of the box represent the upper and the lower quartile
values (Q3/Q1), and the upper and lower horizontal bars outside the box indicate the upper and the lower adjacent values (UAV/LAV). Note that UAV is
the largest observation value that is less than or equal to Q3þ1.5 (Q3–Q1), and LAV is the smallest observation greater than or equal to
Q1–1.5 (Q3–Q1). Black triangle marks represent the median values, and black square marks represent outliers. U0R0: patients without PAC showing no
recurrence within 5 years after surgery. U0R1: patients without PAC in showing recurrence within 5 years after surgery. U1R0: patients who received PAC
with uracil–tegafur and showed no recurrence within 5 years after surgery. U1R1: patients who received PAC with uracil–tegafur and showed recurrence
within 5 years after surgery. (A) These three peptide signals were shown by MS/MS to have originated from myosin IIA. There was a significant difference
between the U1R1 and the other groups (Po9.7 10
 7). (B) These six peptide signals were shown by MS/MS to have originated from vimentin. There
was also a significant difference between the U1R1 and the other groups (Po8.3 10
 6).
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more than 50% of the cells showed immunohistochemical
reactivity for myosin IIA, considered as overexpressing (positive).
We also evaluated overexpressing (positive) cases in which more
than 25% of the cells showed immunohistochemical reactivity for
vimentin. On the basis of these criteria, we evaluated sample sets
A and B.
Immunohistochemical evaluation of sample set A (Table 4A): all
patients with cancers lacking expression of both myosin IIA and
vimentin showed relapse-free survival at 5 years. On the other
hand, all patients with cancers showing positive expression of both
myosin IIA and vimentin suffered disease recurrence.
Immunohistochemical evaluation of sample set B (Table 4B):
among 90 cases, 75 (83.3%) showed overexpression of myosin IIA,
and 48 (53.3%) showed overexpression of vimentin. There was no
Table 3 Amino-acid sequences from the selected peptide ion signals
Name Fraction Sequence
Myosin, heavy polypeptide 9, non-muscle
MYH9_1 Insoluble IRELESQISELQEDLESER
MYH9_2 Insoluble KANLQIDQINTDLNLER
MYH9_3 Insoluble HEMPPHIYAITDTAYR
Vimentin
VIM_1 Insoluble ETNLDSLPLVDTHSK
VIM_2 Insoluble NLQEAEEWYK
VIM_3 Insoluble LGDLYEEEMR
VIM_4 Insoluble LLQDSVDFSLADAINTEFK
VIM_5 Soluble SGDAAIVDMVPGKPMCVESFSDYPPLGR
VIM_6 Soluble ILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNR
Case A
Myosin IIA Vimentin
Case B
Case C
Case D
Figure 2 Immunohistochemical reactivity of representative cases using anti-myosin IIA antibody, ab24762 (abcam, Cambridge, UK) and anti-vimentin
antibody (Dako Cytomation, Denmark A/S). Case A showed positive cytoplasmic staining for both myosin IIA and vimentin. Case B showed positive
cytoplasmic staining for myosin IIA and negative cytoplasmic staining for vimentin. Case C showed negative cytoplasmic staining for myosin IIA and positive
cytoplasmic staining for vimentin. Case D showed negative cytoplasmic staining for both myosin IIA and vimentin.
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myosin IIA and vimentin. All nine patients whose cancers lacked
immunohistochemical reactivity for both myosin IIA and vimentin
showed relapse-free survival at 5 years. Among cases that were
immunohistochemically negative for both myosin IIA and
vimentin, we recognised a statistically significant difference
between U1R1 and U0R0 (P¼0.008), but there were no significant
differences between U1R1 and the other groups.
Disease-free survival and coexpression of myosin IIA and
vimentin in sample set B
The non-relapse survival curves of cases with/without PAC are
shown in Figure 3A and B. Irrespective of whether patients had
undergone PAC or not, the non-relapse survival rate of cases
lacking expression of both myosin IIA and vimentin was 100%.
Among patients who had not undergone PAC, there was a
statistically significant difference between cases lacking expression
of both myosin IIA and vimentin and cases that were positive for
both (P¼0.011) (Figure 3A). Among the patients who received
PAC, there was no statistically significant difference in this respect
(Figure 3B). When the cases showing positive expression of both
myosin IIA and vimentin were evaluated, we recognised a 5-year-
survival rate benefit of approximately 19% in patients who had
undergone PAC with uracil–tegafur, but there was no statistically
significant difference in this respect between patients who had and
who had not received PAC.
When we evaluated the non-relapse survival curves of all the
studied cases, there were statistically significant differences
between cases negative for myosin IIA and vimentin expression
and cases that were positive for both (P¼0.006), and between
cases positive for either myosin IIA or vimentin and cases that
were negative for both (P¼0.029; Figure 4).
DISCUSSION
Lung cancer is the leading cause of cancer death in Japan, and its
incidence is still increasing. Even if surgical resection involving
either lobectomy or pneumonectomy accompanied by lymph node
dissection is performed at a relatively early stage, distant
metastasis often occurs within a few years. More than 20% of
patients with stage I NSCLC suffer recurrence caused by distant
metastasis. Distant metastasis is the most frequent mode of
recurrence in patients who undergo surgical resection of lung
cancer, and it is believed that in such patients, micrometastasis is
Table 4 Relationship between PAC, recurrence and immunohistochem-
ical reactivity for myosin IIA and vimentin
M( )V( )
M( )V(+) or
M(+)V( ) M(+)V(+) ND
(A) Sample set A (n¼24) derived from the same cases as those subjected to LC-MS/
MS
U0R0 5 2 0 0
U1R0 2 3 0 1
U0R1 0 2 4 0
U1R1 0 0 5 0
(B) Sample set B (n¼90) for validation by immunohistochemical analysis
U0R0 6 11 5 0
U1R0 3 12 12 0
* U0R1 0 6 11 0
U1R1 0 10 14 0
M¼expression of myosin IIA; ND¼not done; U0R0¼patients without PAC
showing no recurrence within 5 years after surgery; U0R1¼patients without
PAC showing recurrence within 5 years after surgery; U1R0¼patients who received
PAC with uracil–tegafur and showed no recurrence within 5 years after surgery;
U1R1¼patients who received PAC with uracil–tegafur and showed recurrence
within 5 years after surgery; V¼expression of vimentin. *Statistically significant
difference between U0R0 and U1R1 was detected (P¼0.008).
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Figure 3 Kaplan–Meier curves for disease-free survival after complete
resection in patients with stage I lung adenocarcinoma who received PAC
with uracil–tegafur (A), or did not receive any PAC (B). a: Cases lacking
both myosin IIA and vimentin expression (non-relapse survival rate at 5
years: 100% in panels A and B). b: Cases negative for myosin IIA
expression and positive for vimentin expression, or positive for myosin IIA
and negative for vimentin expression (non-relapse survival rate at 5 years:
64.7% in panel A and 53.7% in panel B). c: Cases positive for both myosin
IIA and vimentin expression (non-relapse survival rate at 5 years: 30.0% in
panel A and 49.0% in panel B). In patients who did not receive adjuvant
chemotherapy, there was a statistically significant difference in disease-free
survival between those who were negative and those who were positive
for both proteins (a–c: P¼0.011). No significant difference in this respect
was recognised in patients who received PAC with uracil–tegafur.
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Figure 4 Kaplan–Meier curves for disease-free survival after complete
resection in patients with stage I lung adenocarcinoma. a: Cases lacking
both myosin IIA and vimentin expression (non-relapse survival rate at 5
years: 100%). b: Cases negative for myosin IIA and positive for vimentin, or
positive for myosin IIA and negative for vimentin (non-relapse survival rate
at 5 years: 58.0%). c: Cases positive for both myosin IIA and vimentin
(non-relapse survival rate at 5 years: 42.0%). Group a: showed significantly
higher survival than group b, and significantly higher survival than group c:
(a–b: P¼0.029; a–c: P¼0.006).
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sinvariably present at the time of initial treatment. If an efficient
PAC regimen could be devised for total control of micrometastasis,
then the prognosis of patients with lung cancer would be markedly
improved. A meta-analysis conducted in the 1990s showed that
PAC using platinum-based agents had no effect on the survival of
patients with NSCLC, even though previous studies had suggested
a 5% increase in survival at 5 years (Non-Small Cell Lung Cancer
Collaborative Group, 1995). At the 2004 ASCO meeting, the results
of two randomised adjuvant trials showing the efficacy of
platinum-based chemotherapy – the CALGB-9633 trial (carbopla-
tin and paclitaxcel) (Strauss et al, 2004) and the JBR 10 trial
(cisplatin and vinorelbine) – were reported. Furthermore, a recent
large-scale randomised clinical trial involving meta-analysis
concluded that patients assigned to cisplatin-based PAC had a
significantly higher survival rate than those assigned to post-
operative observation (44.5 vs 40.4% at 5 years; Po0.03)
(Arriagada et al, 2004). Also our previous study showed that
PAC with uracil–tegafur conferred a survival benefit for patients
with resected stage I adenocarcinoma of the lung (Kato et al, 2004).
Also, meta-analysis of PAC with tegafur–uracil supported this
result (Hamada et al, 2005). However, even though a significant
difference was found in this study, the 5-year-survival rate benefit
of this therapy was 11.5% for stage IB adenocarcinoma (Kato et al,
2004). At present, although leading lung cancer experts appear to
have reached a consensus concerning the effectiveness of PAC,
none of the present PAC regimens are of benefit to more than 15%
of patients with NSCLC. In this context, it is very important to
predict the response to PAC and to select potential responders
before carrying out PAC. Therefore, we attempted to identify
biomarkers of either responders or nonresponders including
relapse-free patients without PAC using uracil–tegafur, for
selection of patients who would benefit from PAC using proteomic
analysis of surgically resected specimens of stage I lung
adenocarcinoma.
As proteins play a role in both physiological and pathological
functions, it is now recognised that investigation of proteins is
essential to obtain an accurate grasp of cellular physiology. Recent
advances in proteomic techniques, including two-dimensional
polyacrylamide gel electrophoresis and MS, have brought hope
that the pathogenesis of any type of malignant neoplasm will be
ultimately clarified. We believe that the present concepts of
proteomic analysis will prove to be extremely valuable in the field
of clinical oncology, and will lead to the development of new
therapeutic strategies. Liquid chromatography-tandem mass spec-
trometry enables simultaneous evaluation of a large number of
polypeptides, and furthermore, MS/MS has made it possible to
identify protein molecules by obtaining information about their
amino-acid sequences. We attempted to identify proteins asso-
ciated with the effectiveness of postoperative uracil–tegafur
chemotherapy and the favourable prognosis of stage I adenocarci-
noma, and detected two kinds of protein molecules (myosin IIA
and vimentin) showing significantly high expression in the group
that suffered recurrence despite administration of uracil–tegafur,
in comparison with the other groups. Our semiquantitative results
of LC-MS were confirmed by immunohistochemistry for myosin
IIA and vimentin (Table 4A).
Nonmuscle myosin IIA is a major component of the actomyosin
cytoskeleton and is generally considered to contribute to contrac-
tion of the cell posterior during migration (Ridley et al, 2003).
However, there is still a profound lack of understanding of the
exact mechanical roles of myosin IIA during cell migration. A
recent clinical study of patients with NSCLC found a significant
positive correlation between the expression levels of myosin light
chain kinase (which activates myosin II) and the likelihood of
disease recurrence and metastasis (Minamiya et al, 2005),
indicating that myosin IIA activation could be a factor contribut-
ing to metastasis. A key role for myosin IIA in cancer cell
metastasis has been further suggested, indirectly, by a number of
published studies focusing on the small calcium-binding protein,
metastasin-1. This protein is upregulated in many metastasis cell
lines, and when overexpressed enhances metastatic behaviour
(Davies et al, 1993). A major cellular target of metastasin-1 seems
to be myosin IIA (Garrett et al, 2006). Although studies of
metastasin-1 suggest critical roles for myosin IIA in metastasis,
it remains completely unknown how myosin IIA contributes to
metastasis, and which isoforms are important for this process.
Vimentin is the most ubiquitous intermediate filament protein
and the first to be expressed during cell differentiation. All
primitive cell types express vimentin, but in most nonmesen-
chymal cells, it is replaced by other intermediate filament proteins
during differentiation. Vimentin is expressed in a wide variety of
mesenchymal cell types (fibroblasts, endothelial cells, etc), and
also in a number of other cell types derived from mesoderm,
mesothelium and ovarian granulose cells. Epithelial–mesenchymal
transition is a key mechanism operating in the normal develop-
ment of multicellular organisms. During this process, epithelial
cells progressively acquire a reversible or irreversible mesenchy-
mal phenotype that is essential for organogenesis (Thiery, 2002).
Morphogenetic epithelial–mesenchymal transition is aberrantly
recapitulated during tumorigenesis in a variety of epithelial
cancers, including those of the thyroid, liver, kidney, prostate,
breast and lung (Arias, 2001; Thiery, 2002). The common signature
of this process involves disruption of normal epithelial integrity,
with loss of morphological features including polarised epithelia,
and partial or total gain of mesenchymal markers with progressive
acquisition of a motile and invasive phenotype (Islam et al, 1996).
In addition to a disrupted epithelial morphology, dysregulation of
adhesion and junctional molecules and aberrant expression of
N-cadherin, epithelial–mesenchymal transition involves de novo
expression of other mesenchymal markers, such as fibronectin and
vimentin in epithelial cells. Aberrant expression of vimentin in
tumours and transformed cell lines has been correlated with
increased motility, invasive behaviour and poor prognosis (Gilles
et al, 1996; Hendrix et al, 1997). Recently, it was reported that the
presence of vimentin-positive tumour cells mainly in fibrotic areas
is consistent with other studies that have shown a correlation
between tumour fibrosis and epithelial–mesenchymal transition
(Blanco et al, 2004).
These two molecules identified by proteomic analysis might reflect
the cellular functions of metastasis and the mechanism of recurrence
of malignant neoplasms. We attempted to validate the results of
LC-MS/MS using immunohistochemistry of an additional sample
set (sample set B: 90 surgically resected lung cancer specimens) with
monoclonal antibodies against the two proteins. The results showed
that cases lacking expression of the two proteins had a good
prognosis, irrespective of whether the patients had undergone PAC.
Therefore, these two proteins appear to be potentially useful
biomarkers for the selection of patients who do not require PAC.
In the cases positive for both of these proteins, the 5-year-survival
benefit was approximately 19% in patients with adenocarcinoma
who underwent PAC with uracil–tegafur. However, there was no
significant difference between patients who did, and did not,
undergo PAC with uracil–tegafur. Therefore, in this investigation,
we failed to select patients who might benefit from this adjuvant
chemotherapy. A larger-scale investigation is therefore needed to
establish suitable biomarkers for the selection of patients who might
benefit from PAC with uracil–tegafur, because a few per cent of
patients with stage I adenocarcinoma do obtain such a benefit.
Individualised chemotherapy for lung cancer patients is
currently attracting attention, because the efficacy of systemic
chemotherapy using any single agent is less than 30%. Therefore, it
is extremely important to select patients who might benefit from
chemotherapy. Until an ideal chemotherapy agent is established,
we propose that rather than focusing only on improving the
efficacy of chemotherapy regimens, we should also make efforts to
identify patients who will show a good response to regimens that
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of evidence-based medicine. In this situation, positive indicators
for the effectiveness of PAC with uracil–tegafur are needed.
However, in this study, we were unable to detect novel biomarkers
for selection of good responders. The two protein molecules
detected in this proteomic analysis were biomarkers indicative of
good prognosis.
The ultimate purpose of clinical proteomics is to improve
diagnostic procedures including the exact evaluation of biological
characteristics of tumour cells and to understand the molecular
pathogenesis of cancers to devise novel therapeutic strategies. We
believe that proteomic analysis will become an integral tool for
investigation of tumour biology. We conclude that negative
expression of both myosin IIA and vimentin is an indicator of
good prognosis for stage I lung adenocarcinoma without the need
for PAC.
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